throbber
HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`
` These highlights do not include all the information needed to use
`CYMBALTA safely and effectively. See full prescribing
`
`
` information for CYMBALTA.
`
`•
`
`
` In linezolid- or intravenous methylene blue-treated patients,
`
`
`
`
` initiation of CYMBALTA is contraindicated (4)
`
`
`
` 1
`
`
`
`
`
` CYMBALTA (duloxetine delayed-release capsules), for oral use
`
` Initial U.S. Approval: 2004
`
`
`
`
`
` WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
`
`
`
`
`
`
`
` See full prescribing information for complete boxed warning.
`
`Increased risk of suicidal thinking and behavior in children,
`
` adolescents, and young adults taking antidepressants (5.1)
`• Monitor for worsening and emergence of suicidal thoughts
`
`
`
` and behaviors (5.1)
`
`•
`
`
`
`
`•
`
`
`
`
`
`
`
` ------------------------ WARNINGS AND PRECAUTIONS -----------------------
`• Hepatotoxicity: Hepatic failure, sometimes fatal, has been
`
`reported. Discontinue CYMBALTA in patients who develop
`
` jaundice or other evidence of clinically significant liver dysfunction
`and should not be resumed unless another cause can be
`
` established. Avoid use in patients with substantial alcohol use or
` evidence of chronic liver disease (5.2)
`
`• Orthostatic Hypotension, Falls and Syncope: Consider dosage
`
`
` reduction or discontinuation if these events occur (5.3)
`
`
`• Serotonin Syndrome: Increased risk when co-administered with
`
`
` other serotonergic agents, but also when taken alone. If it occurs,
`
`
` discontinue CYMBALTA and serotonergic agents (5.4)
`
`
`
`
`Increased Risk of Bleeding: May increase the risk of bleeding
` events. Concomitant use of antiplatelet drugs and anticoagulants
`
` may increase this risk (5.5, 7.4, 8.1)
`
`• Severe Skin Reactions: Severe skin reactions, including erythema
`
`
`
` multiforme and Stevens-Johnson Syndrome (SJS), can occur;
`
`Discontinue at the first appearance of blisters, peeling rash,
`
`
` mucosal erosions, or any other sign of hypersensitivity if no other
` etiology can be identified (5.6)
`
`
`• Activation of Mania or Hypomania: Prior to initiating, screen
`
`
`patients for personal or family history of bipolar disorder, mania, or
`
`
` hypomania (5.8)
`• Angle-Closure Glaucoma: Has occurred in patients with untreated
`
`
`
` anatomically narrow angles treated with antidepressants (5.9)
`• Seizures: Prescribe with care in patients with a history of seizure
`
`
` disorder (5.10)
`• Blood Pressure Increases: Monitor blood pressure prior to initiating
`
`
` treatment and periodically throughout treatment (5.11)
`
` Inhibitors of CYP1A2 or Thioridazine: Avoid co-administration with
`
`
`
` CYMBALTA (5.12)
`• Hyponatremia: Can occur in association with SIADH; consider
`
`
`
` discontinuation (5.13)
`• Glucose Control in Diabetes: In DPNP patients, increases in
`
`
` fasting blood glucose, and HbA1c have been observed (5.14)
`
`
`
`
`• Conditions that Slow Gastric Emptying: Use cautiously in these
`
`
` patients (5.14)
`• Sexual Dysfunction: CYMBALTA may cause symptoms of sexual
`
`
`
`
` dysfunction (5.16)
`
`
`
`
`
`
`
` --------------------------- RECENT MAJOR CHANGES --------------------------
`
`
`
`
`
` Warnings and Precautions (5.4, 5.5)
`
`
`
` 8/2023
`
` ---------------------------- INDICATIONS AND USAGE ---------------------------
`
`
`
`
` CYMBALTA® is a serotonin and norepinephrine reuptake inhibitor
` (SNRI) indicated for the treatment of the following conditions:
`
`
`• Major depressive disorder (MDD) in adults (1)
`
`
`
`• Generalized anxiety disorder (GAD) in adults and pediatric patients
`
`
`
` 7 years of age and older (1)
`
`• Diabetic peripheral neuropathic pain (DPNP) in adults (1)
`
`
`
`
`
`
`• Fibromyalgia (FM) in adults and pediatric patients 13 years of age
`
` and older (1)
`
`• Chronic musculoskeletal pain in adults (1)
`
`
`
`
`
`
`
`
`
`
`
` ------------------------DOSAGE AND ADMINISTRATION -----------------------
`• Take CYMBALTA once daily, with or without food. Swallow whole;
`
`
`
`
`
` do not crush, chew, or open capsule (2.1)
`
`
`
`
`
` Indication
`
`
`
` MDD (2.2)
`
`Starting
`
` Dose
`
`
`
` Target Dose
`
`
`
` 40 mg/day
`to 60
` mg/day
`
`
`
`Acute Treatment: 40
`mg/day (20 mg twice
`
` daily) to 60 mg/day
`(once daily or as 30 mg
`twice daily);
`Maintenance
` Treatment: 60 mg/day
`
`
`
`Maximum
`
` Dose
`
`
`
` 120 mg/day
`
`
`
` GAD (2.3)
`
`
`
`
`
`
`
` Adults
`
` 60 mg/day
`
`
`
` 60 mg/day (once daily)
`
`
`
` 120 mg/day
`
`•
`
`
`
`
`
`
`
`
` ------------------------------- ADVERSE REACTIONS ------------------------------
`Most common adverse reactions (≥5% and at least twice the incidence
`
`
`
` of placebo-treated patients): (6.1)
` Adults: nausea, dry mouth, somnolence, constipation, decreased
`
` appetite, and hyperhidrosis
`Pediatric Patients: decreased weight, decreased appetite, nausea,
`
` vomiting, fatigue, and diarrhea
`
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly
`and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-
`
` FDA-1088 or www.fda.gov/medwatch.
`
`
`
`
` ------------------------------- DRUG INTERACTIONS ------------------------------
`• Potent inhibitors of CYP1A2 should be avoided (7.1)
`
`
`• Potent inhibitors of CYP2D6 may increase CYMBALTA
`
`
` concentrations (7.2)
`
`• CYMBALTA is a moderate inhibitor of CYP2D6 (7.9)
`
`
`
`
`
`
` ------------------------USE IN SPECIFIC POPULATIONS-----------------------
`
`
`
`
`Pregnancy: Third trimester use may increase risk for symptoms of poor
`adaptation (respiratory distress, temperature instability, feeding
`
`
` difficulty, hypotonia, tremor, irritability) in the neonate (8.1)
`Hepatic Impairment: Avoid use in patients with chronic liver disease or
`
` cirrhosis (5.14)
`Renal Impairment: Avoid use in patients with severe renal impairment,
`
` GFR <30 mL/minute (5.14)
`
`
`
` See 17 for PATIENT COUNSELING INFORMATION and FDA-
`
` approved Medication Guide.
`
`
`
` Revised: 8/2023
`
`
`
`
`
`
`
` Geriatric
`
`
`
` 30 mg/day
`
`
`
` 60 mg/day (once daily)
`
`
`
` 120 mg/day
`
` Pediatrics (7
`
`to 17 years
`
` of age)
`
`
`
` 30 mg/day
`
`
`
` 30 to 60 mg/day (once
`
` daily)
`
`
`
` 120 mg/day
`
`
`
` DPNP (2.4)
`
`
`
` 60 mg/day
`
`
`
` 60 mg/day (once daily)
`
`
`
` 60 mg/day
`
`
`
` FM (2.5)
`
`
`
` 30 mg/day
`
`
`
` 60 mg/day (once daily)
`
`
`
` 60 mg/day
`
`
`
`
`
`
`
`Adults and
`
` Pediatrics
`
` (13 to 17
` years of
`
`
` age)
`
`
`
` 30 mg/day
`
`
`
` 60 mg/day (once daily)
`
` Chronic
`
`Musculoskel
`etal Pain
`
` (2.6)
`• Discontinuing CYMBALTA: Gradually reduce dosage to avoid
`
`
`
` discontinuation symptoms (2.8, 5.7)
`
`
`
` 60 mg/day
`
` ----------------------DOSAGE FORMS AND STRENGTHS---------------------
`
`
`
`
` Delayed-release capsules: 20 mg, 30 mg, and 60 mg (3)
`
`
`
`
`
`
` ------------------------------- CONTRAINDICATIONS ------------------------------
`• Concomitant use of an MAOI antidepressant with CYMBALTA is
`
`
`
` contraindicated
`• Use of CYMBALTA within 14 days of stopping an MAOI
`
`
` antidepressant is contraindicated
`
`
`
`
`
`
`
`Reference ID: 5229383
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
` 2
`
` Drugs that Affect Gastric Acidity
`
`
` 7.7
`
` Drugs Metabolized by CYP1A2
`
` 7.8
`
` Drugs Metabolized by CYP2D6
`
` 7.9
`
`
` 7.10 Drugs Metabolized by CYP2C9
`
` 7.11 Drugs Metabolized by CYP3A
`
`
`
` 7.12 Drugs Metabolized by CYP2C19
`
` 7.13 Monoamine Oxidase Inhibitors (MAOIs)
`
`
` 7.14 Other Serotonergic Drugs
`
`
` 7.15 Alcohol
`
`
`
` 7.16 CNS Drugs
`
` 7.17 Drugs Highly Bound to Plasma Protein
`
`
`
`
`
`
`
`
`
` 8 USE IN SPECIFIC POPULATIONS
`
`
` 8.1
` Pregnancy
`
` 8.2
`
` Lactation
`
` 8.4
` Pediatric Use
`
`
` 8.5
`
` Geriatric Use
`
` 8.6
`
` Gender
`
` 8.7
` Smoking Status
`
` 8.8
`
` Race
`
`
`
` 8.9
` Hepatic Impairment
` 8.10 Severe Renal Impairment
`
`
`
`
`
`
`
`
`
`
`
`
` 9 DRUG ABUSE AND DEPENDENCE
`
`
` 9.2
` Abuse
`
` 9.3
` Dependence
`
`
`
`
`
` 10 OVERDOSAGE
`
`
`
` 10.1 Signs and Symptoms
`
` 10.2 Management of Overdose
`
`
`
`
`
`
` 11 DESCRIPTION
`
`
`
`
`
` 12 CLINICAL PHARMACOLOGY
`
`
` 12.1 Mechanism of Action
`
` 12.2 Pharmacodynamics
`
`
` 12.3 Pharmacokinetics
`
`
`
`
`
`
` 13 NONCLINICAL TOXICOLOGY
`
`
` 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`
`
`
`
` 14 CLINICAL STUDIES
`
`
`
` 14.1 Overview of the Clinical Trials
`
` 14.2 Major Depressive Disorder in Adults
`
`
` 14.3 Generalized Anxiety Disorder
`
`
` 14.4 Diabetic Peripheral Neuropathic Pain in Adults
`
` 14.5 Fibromyalgia
`
`
` 14.6 Chronic Musculoskeletal Pain in Adults
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
` 16.1 How Supplied
`
` 16.2 Storage and Handling
`
`
`
`
`
`
` 17 PATIENT COUNSELING INFORMATION
`
`
`
`
`
`* Sections or subsections omitted from the full prescribing information
`
`are not listed.
`
`
`
`
`
`
`
` FULL PRESCRIBING INFORMATION: CONTENTS*
`
`
`
` WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
`
`
`
` 1
`
`
`
` INDICATIONS AND USAGE
`
`
`
` 2 DOSAGE AND ADMINISTRATION
`
`
` 2.1
` Important Administration Instructions
`
`
` 2.2
`
`
` Dosage for Treatment of Major Depressive Disorder in
`
` Adults
` Dosage for Treatment of Generalized Anxiety Disorder
`
`
`
` Dosage for Treatment of Diabetic Peripheral Neuropathic
`
`
` Pain in Adults
` Dosage for Treatment of Fibromyalgia
`
` Dosage for Treatment of Chronic Musculoskeletal Pain in
`
` Adults
`Dosage in Patients with Hepatic Impairment or Severe
`
` Renal Impairment
` Discontinuing CYMBALTA
`
`
` Switching a Patient to or from a Monoamine Oxidase
` Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
`
`
`
` 2.10 Use of CYMBALTA with Other MAOIs such as Linezolid or
`
` Methylene Blue
`
`
`
`
`
`
`
`
`
`
` 2.3
`
` 2.4
`
`
` 2.5
`
` 2.6
`
`
`
` 2.7
`
`
` 2.8
`
` 2.9
`
`
`
`
`
` 3 DOSAGE FORMS AND STRENGTHS
`
`
`
`
`
` 4 CONTRAINDICATIONS
`
`
`
`
`
` 5 WARNINGS AND PRECAUTIONS
`
`
` 5.1
`Suicidal Thoughts and Behaviors in Children,
`
`
` Adolescents, and Young Adults
` Hepatotoxicity
`
`
` 5.2
` Orthostatic Hypotension, Falls and Syncope
`
` 5.3
`
` Serotonin Syndrome
`
` 5.4
` Increased Risk of Bleeding
`
`
` 5.5
`
` Severe Skin Reactions
`
` 5.6
` Discontinuation Syndrome
`
`
` 5.7
` Activation of Mania/Hypomania
`
` 5.8
`
` Angle-Closure Glaucoma
`
` 5.9
`
`
` 5.10 Seizures
` Increases in Blood Pressure
`
`
`
` 5.11
`
` 5.12 Clinically Important Drug Interactions
`
` 5.13 Hyponatremia
`
`
` 5.14 Use in Patients with Concomitant Illness
`
` 5.15 Urinary Hesitation and Retention
`
`
` 5.16 Sexual Dysfunction
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 6 ADVERSE REACTIONS
`
`
`
`
`
` 6.1
` Clinical Trials Experience
`
` 6.2
` Postmarketing Experience
`
`
`
`
` 7 DRUG INTERACTIONS
`
`
` 7.1
`
` Inhibitors of CYP1A2
`
` 7.2
`
` Inhibitors of CYP2D6
`
` 7.3
` Dual Inhibition of CYP1A2 and CYP2D6
`
`
` 7.4
`Drugs that Interfere with Hemostasis (e.g., NSAIDs,
`
` Aspirin, and Warfarin)
`
` Lorazepam
` Temazepam
`
`
`
` 7.5
`
` 7.6
`
`
`
`Reference ID: 5229383
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
` FULL PRESCRIBING INFORMATION
`
`
`
` 3
`
`
`
` WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
`
`
`
`Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young
`adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and
`behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant
`
` use in patients aged 65 and older [see Warnings and Precautions (5.1)].
`
`In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for
`
` emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close
` observation and communication with the prescriber [see Warnings and Precautions (5.1)].
`
`
`
`
` 1
`
`
`
` INDICATIONS AND USAGE
`
`
`
` CYMBALTA® is indicated for the treatment of:
`
`
`
`• Major depressive disorder in adults
`
`
`
`• Generalized anxiety disorder in adults and pediatric patients 7 years of age and older
`
`
`
`• Diabetic peripheral neuropathic pain in adults
`
`
`
`• Fibromyalgia in adults and pediatric patients 13 years of age and older
`
`
`
`• Chronic musculoskeletal pain in adults
`
`
`
`
`
`
` 2
`
`
`
` DOSAGE AND ADMINISTRATION
`
`
`
` 2.1
`
`
`
` Important Administration Instructions
`
`
`
`
`
`
`
` Administer CYMBALTA orally (with or without meals) and swallow whole. Do not chew or crush, and do not open the
`
` delayed-release capsule and sprinkle its contents on food or mix with liquids because these actions might affect the
`
`
`
`enteric coating. If a dose of CYMBALTA is missed, take the missed dose as soon as it is remembered. If it is almost time
`
` for the next dose, skip the missed dose and take the next dose at the regular time. Do not take two doses of CYMBALTA
`
` at the same time.
`
`
`
` 2.2
`
`
`
` Dosage for Treatment of Major Depressive Disorder in Adults
`
`
`
` The recommended starting dosage in adults with MDD is 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given
`
`
`
`
`
`
`
` either once daily or as 30 mg twice daily). For some patients, it may be desirable to start at 30 mg once daily for 1 week,
` to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. While a 120 mg/day dose was shown to
`
`
`
`
` be effective, there is no evidence that doses greater than 60 mg/day confer any additional benefits. Periodically reassess
` to determine the need for maintenance treatment and the appropriate dosage for such treatment.
`
`
`
`
`
`
` 2.3
`
`
`
` Dosage for Treatment of Generalized Anxiety Disorder
`
`
`
`
`
` Recommended Dosage in Adults Less than 65 Years of Age
`
`
`
`
`
`
`
` For most adults less than 65 years of age with GAD, initiate CYMBALTA 60 mg once daily. For some patients, it may be
`
`
`
`
`
` desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg
` once daily. While a 120 mg once daily dosage was shown to be effective, there is no evidence that doses greater than
`
`
` 60 mg/day confer additional benefit. Nevertheless, if a decision is made to increase the dosage beyond 60 mg once daily,
`
`
` increase dosage in increments of 30 mg once daily. Periodically reassess to determine the continued need for
`
`
`
`
` maintenance treatment and the appropriate dosage for such treatment.
`
`
`
`
`
`
` Recommended Dosage in Geriatric Patients
`
` In geriatric patients with GAD, initiate CYMBALTA at a dosage of 30 mg once daily for 2 weeks before considering an
`
`
`
`
` increase to the target dose of 60 mg/day. Thereafter, patients may benefit from doses above 60 mg once daily. If a
` decision is made to increase the dose beyond 60 mg once daily, increase dose in increments of 30 mg once daily. The
`
`
`
`
`
` maximum dose studied was 120 mg per day.
`
`
`
`
`
`
`
`
` Recommended Dosage in Pediatric Patients 7 to 17 Years of Age
`
`
`
`
`
`
`
`
`
` Initiate CYMBALTA in pediatric patients 7 to 17 years of age with GAD at a dosage of 30 mg once daily for 2 weeks
` before considering an increase to 60 mg once daily. The recommended dosage range is 30 to 60 mg once daily. Some
`
`
`
`
`
`
` patients may benefit from dosages above 60 mg once daily. If a decision is made to increase the dose beyond 60 mg
` once daily, increase dosage in increments of 30 mg once daily. The maximum dose studied was 120 mg per day.
`
`
`
`Reference ID: 5229383
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
` 2.4
`
`
`
` Dosage for Treatment of Diabetic Peripheral Neuropathic Pain in Adults
`
`
`
` Administer 60 mg once daily in adults with diabetic peripheral neuropathic pain. There is no evidence that doses higher
`
`
`
`
`
`
` than 60 mg once daily confer additional significant benefit and the higher dosage is clearly less well tolerated. For patients
` for whom tolerability is a concern, a lower starting dose may be considered.
`
`
` Since diabetes is frequently complicated by renal disease, consider a lower starting dosage and gradual increase in
`
`
`
`
` dosage for patients with renal impairment [see Dosage and Administration (2.7) and Use in Specific Populations (8.10)].
`
`
`
`
`
` 2.5
`
`
`
` Dosage for Treatment of Fibromyalgia
`
`
`
` 4
`
`
`
` Recommended Dosage in Adults
`
`
`
`
`
`
`
`
`
`
` The recommended CYMBALTA dosage is 60 mg once daily in adults with fibromyalgia. Begin treatment at 30 mg once
` daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. Some patients may
`
`
`
` respond to the starting dosage. There is no evidence that dosages greater than 60 mg/day confer additional benefit, even
` in patients who do not respond to a 60 mg/day dosage, and higher dosages were associated with a higher rate of adverse
`
`
`
`
`
`
` reactions.
`
`
`
`
`
` Recommended Dosage in Pediatric Patients 13 to 17 Years of Age
`
`
`
`
`
`
`
`
`
` The recommended starting CYMBALTA dosage in pediatric patients 13-17 years of age with fibromyalgia is 30 mg once
`
`
`
` daily. The dosage may be increased to 60 mg once daily based on response and tolerability.
`
`
`
`
`
` 2.6
`
`
`
` Dosage for Treatment of Chronic Musculoskeletal Pain in Adults
`
`
`
`
`
` The recommended CYMBALTA dosage is 60 mg once daily in adults with chronic musculoskeletal pain. Begin treatment
`
`
`
`
`
`
`
`
` at 30 mg once daily for one week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. There
` is no evidence that higher dosages confer additional benefit, even in patients who do not respond to a 60 mg once daily
`
`
`
`
` dosage, and higher dosages are associated with a higher rate of adverse reactions [see Clinical Studies (14.6)].
`
`
`
` 2.7
`
`
`
` Dosage in Patients with Hepatic Impairment or Severe Renal Impairment
`
`
`
`
`
` Avoid use in patients with chronic liver disease or cirrhosis [see Warnings and Precautions (5.14) and Use in Specific
`
` Populations (8.9)].
`
` Avoid use in patients with severe renal impairment, GFR <30 mL/minute [see Warnings and Precautions (5.14) and Use in
`
`
` Specific Populations (8.10)].
`
`
`
`
`
`
`
`
`
` 2.8
`
`
`
` Discontinuing CYMBALTA
`
` Adverse reactions after discontinuation of CYMBALTA, after abrupt or tapered discontinuation, include: dizziness,
`
`
`
`
`
` headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue. A gradual
` reduction in dosage rather than abrupt cessation is recommended whenever possible [see Warnings and Precautions
`
`
`
` (5.7)].
`
`
`
` 2.9
`
`
`
` Switching a Patient to or from a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric
`
` Disorders
`
`
`
` At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of
`
`
`
` therapy with CYMBALTA. Conversely, at least 5 days should be allowed after stopping CYMBALTA before starting an
`
`
` MAOI intended to treat psychiatric disorders [see Contraindications (4)].
`
`
`
` 2.10 Use of CYMBALTA with Other MAOIs such as Linezolid or Methylene Blue
`
`
`
`
`
` Do not start CYMBALTA in a patient who is being treated with linezolid or intravenous methylene blue because there is an
`
`increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other
`
` interventions, including hospitalization, should be considered [see Contraindications (4)].
`
` In some cases, a patient already receiving CYMBALTA therapy may require urgent treatment with linezolid or intravenous
`
`
` methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the
`potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin
`
`
` syndrome in a particular patient, CYMBALTA should be stopped promptly, and linezolid or intravenous methylene blue
` can be administered. The patient should be monitored for symptoms of serotonin syndrome for 5 days or until 24 hours
`
`
` after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with CYMBALTA may be
` resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see Warnings and Precautions (5.4)].
`
`
`
`Reference ID: 5229383
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

` The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in
`
`
`
` intravenous doses much lower than 1 mg/kg with CYMBALTA is unclear. The clinician should, nevertheless, be aware of
` the possibility of emergent symptoms of serotonin syndrome with such use [see Warnings and Precautions (5.4)].
`
`
`
`
`
` 5
`
`
`
` 3
`
`
`
` DOSAGE FORMS AND STRENGTHS
`
`
`
` CYMBALTA is available as delayed-release capsules:
`
`
`
`
`
`•
`
`•
`
`•
`
`
`20 mg opaque green capsules imprinted with “Lilly 3235 20mg”
`
`
`30 mg opaque white and blue capsules imprinted with “Lilly 3240 30mg”
`
`
`60 mg opaque green and blue capsules imprinted with “Lilly 3270 60mg”
`
`
`
`
`
` 4
`
`
`
` CONTRAINDICATIONS
`
` The use of MAOIs intended to treat psychiatric disorders with CYMBALTA or within 5 days of stopping treatment with
`
`
`
`
`
`
`
`
` CYMBALTA is contraindicated because of an increased risk of serotonin syndrome. The use of CYMBALTA within 14
` days of stopping an MAOI intended to treat psychiatric disorders is contraindicated [see Dosage and Administration (2.8)
`
`
`
` and Warnings and Precautions (5.4)].
`
` Starting CYMBALTA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also
`
`
`contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.9) and Warnings
`
` and Precautions (5.4)].
`
`
`
` 5
`
`
`
` WARNINGS AND PRECAUTIONS
`
`
`
` 5.1
`
`
`
` Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
`
` Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression
`
`
`
` and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they
`are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk
`of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of
` suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of
`
` depression and the emergence of suicidality in certain patients during the early phases of treatment.
`
`
`
`Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these
`drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-
`
` 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in
`the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with
`
` antidepressants compared to placebo in adults aged 65 and older.
`
`The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder
`
` (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400
` patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total
`
`
` of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was
` considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for
`
`almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the
`
` highest incidence in MDD. The risk of differences (drug vs placebo), however, were relatively stable within age strata and
` across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients
`
`
`
` treated) are provided in Table 1.
`
`
`
`
`
`Reference ID: 5229383
`
`
`
` Age Range
`
`
` <18
`
` 18-24
`
`
`
` 25-64
`≥65
`
`
`
`
` Table 1
`
`Drug-Placebo Difference in Number of Cases of
`
` Suicidality per 1000 Patients Treated
`
` Increases Compared to Placebo
` 14 additional cases
`
`
` 5 additional cases
` Decreases Compared to Placebo
`
`
` 1 fewer case
`
` 6 fewer cases
`
`
`
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
` 6
` No suicides occurred in any of the pediatric CYMBALTA trials. There were suicides in the adult CYMBALTA trials, but the
`
`
`
`
`
` number was not sufficient to reach any conclusion about CYMBALTA effect on suicide.
`
` It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is
`
`
`substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants
`
` can delay the recurrence of depression.
`
`All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely
`
` for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of
`
` drug therapy, or at times of dose changes, either increases or decreases.
`
`The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity,
`akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being
`
` treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and
` nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression
`
`
` and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent
`
` precursors to emerging suicidality.
`
`Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in
`
` patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be
`precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not
`part of the patient’s presenting symptoms.
`
`
` If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with
`
`recognition that discontinuation can be associated with certain symptoms [see Dosage and Administration (2.8) and
`
`
`
` Warnings and Precautions (5.7)] for descriptions of the risks of discontinuation of CYMBALTA.
`
`
`
`
`
`
` Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications,
`
` both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation,
`
`
` irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of
`
`
`suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily
`
` observation by families and caregivers. Prescriptions for CYMBALTA should be written for the smallest quantity of
` capsules consistent with good patient management, in order to reduce the risk of overdose.
`
`
`
`
`
` Screening Patients for Bipolar Disorder
`
`
`
`A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not
` established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of
`precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described
`above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with
`depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening
`
` should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It
`
`
` should be noted that CYMBALTA is not approved for use in treating bipolar depression.
`
`
`
` 5.2
`
`
`
` Hepatotoxicity
`
` There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA. These cases have
`
`presented as hepatitis with abdominal pain, hepatomegaly, and elevation of transaminase levels to more than twenty
`times the upper limit of normal (ULN) with or without jaundice, reflecting a mixed or hepatocellular pattern of liver injury.
`
`
` CYMBALTA should be discontinued in patients who develop jaundice or other evidence of clinically significant liver
` dysfunction and should not be resumed unless another cause can be established.
`
`
` Cases of cholestatic jaundice with minimal elevation of transaminase levels have also been reported. Other postmarketing
`
`reports indicate that elevated transaminases, bilirubin, and alkaline phosphatase have occurred in patients with chronic
`
` liver disease or cirrhosis.
`
` CYMBALTA increased the risk of elevation of serum transaminase levels in development program clinical trials. Liver
`
`
`
`
` transaminase elevations resulted in the discontinuation of 0.3% (92/34,756) of CYMBALTA-treated patients. In most
` patients, the median time to detection of the transaminase elevation was about two months. In adult placebo-controlled
`
`
`
`
` trials, for patients with normal and abnormal baseline ALT values, elevation of ALT >3 times the ULN occurred in 1.25%
` (144/11,496) of CYMBALTA-treated patients compared to 0.45% (39/8716) of placebo-treated patients. In adult placebo-
`
`controlled studies using a fixed dose design, there was evidence of a CYMBALTA dose response relationship for ALT and
`
`
` AST elevation of >3 times the ULN and >5 times the ULN, respectively.
`
`
`
`
`
`
` Because it is possible that CYMBALTA and alcohol may interact to cause liver injury or that CYMBALTA may aggravate
`
` pre-existing liver disease, CYMBALTA should not be prescribed to patients with substantial alcohol use or evidence of
`
`
` chronic liver disease.
`
`Reference ID: 5229383
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
` 5.3
`
`
`
` Orthostatic Hypotension, Falls and Syncope
`
`
`
` 7
`
`
`
`
`
` Orthostatic hypotension, falls, and syncope have been reported in patients treated with the recommended CYMBALTA
`
` dosages. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time
` during CYMBALTA treatment, particularly after dose increases. The risk of falling appears to be related to the degree of
`
` orthostatic decrease in blood pressure (BP) as well as other factors that may increase the underlying risk of falls.
`
`
`
`
`
`
` In an analysis of patients from all placebo-controlled trials, patients treated with CYMBALTA reported a higher rate of falls
`
`
`
` compared to patients treated with placebo. Risk appears to be related to the presence of orthostatic decrease in BP. The
` risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such
`
`
`
`
` as antihypertensives) or are potent CYP1A2 inhibitors [see Warnings and Precautions (5.12) and Drug Interactions (7.1)]
` and in patients taking CYMBALTA at doses above 60 mg daily. Consideration should be given to dose reduction or
`
`
`
`
`
` discontinuation of CYMBALTA in patients who experience symptomatic orthostatic hypotension, falls and/or syncope
` during CYMBALTA therapy.
`
`
`
`Risk of falling also appeared to be proportional to a patient’s underlying risk for falls and appeared to increase steadily
`
` with age. As geriatric patients tend to have a higher underlying risk for falls due to a higher prevalence of risk factors such
`as use of multiple medications, medical comorbidities and gait disturbances, the impact of increasing age by itself is
`
` unclear. Falls with serious consequences including fractures and hospitalizations have been reported with CYMBALTA
`
`
` use [see Adverse Reactions (6.1)].
`
`
`
` 5.4
`
`
`
` Serotonin Syndrome
`
` Serotonin-norepinephrine reuptake inhibitors (SNRIs), including CYMBALTA, can precipitate serotonin syndrome, a
`
`
`
` potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including
` triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone,
`
`
`
`
`
` amphetamines, and St. John’s Wort) and

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket